{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/restless-legs-syndrome/prescribing-information/ropinirole/","result":{"pageContext":{"chapter":{"id":"1664194f-800a-54c6-bd79-106678653aaa","slug":"ropinirole","fullItemName":"Ropinirole","depth":2,"htmlHeader":"<!-- begin field 7c2867a3-9a78-460d-83b0-72723fb7d08f --><h2>Ropinirole</h2><!-- end field 7c2867a3-9a78-460d-83b0-72723fb7d08f -->","summary":"","htmlStringContent":"<!-- begin item 462db0de-ab77-4f2c-abfc-05e179c09d93 --><!-- end item 462db0de-ab77-4f2c-abfc-05e179c09d93 -->","topic":{"id":"ce2c49b0-9c88-5bbe-b742-179c3a41de7d","topicId":"8560b6b4-74c4-48fb-99b2-1738f7bdfc1c","topicName":"Restless legs syndrome","slug":"restless-legs-syndrome","lastRevised":"Last revised in November 2020","chapters":[{"id":"0c5685ed-e78f-5c68-8983-83a722c74100","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e6a7ab99-3bce-5334-8352-694d31ef5cc0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"461085e4-b723-57af-8f1a-16da6b5276cd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8a4d8c25-f2fc-5706-989b-f6210f6e1fb8","slug":"changes","fullItemName":"Changes"},{"id":"08d30779-72aa-5609-89bb-35fa111203a1","slug":"update","fullItemName":"Update"}]},{"id":"8544bde0-46f9-502a-aec7-2a5a2d449009","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c04c9edd-95d7-5e3f-94ea-5c7ecd6205a8","slug":"goals","fullItemName":"Goals"},{"id":"4d33d470-bfd2-518f-aebb-b9e86daa02ab","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ab4dd298-08f9-5497-81cd-0ab7e978b675","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8d907e60-5b96-5b39-a188-b481acc2935a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"330f64fa-36dd-5bd9-847c-b379cdd7b437","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9a4d2e02-acae-5411-92f3-bca31ce98b25","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"877ed575-950a-5933-ae1f-abcee48927b8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"623e0c19-8a9e-5892-b3f3-a72ab9d617ce","slug":"definition","fullItemName":"Definition"},{"id":"f6fe6742-330a-5aea-8b52-b32fc2b3ab48","slug":"causes","fullItemName":"Causes"},{"id":"7a8e05a8-1db9-5aac-9b56-c5be8e7eb9d6","slug":"prevalence","fullItemName":"Prevalence"},{"id":"86293e20-8427-58da-8512-93f22162d764","slug":"prognosis","fullItemName":"Prognosis"},{"id":"043ee2a1-37c5-5b2f-8d10-0a9d2d41abe0","slug":"complications","fullItemName":"Complications"}]},{"id":"0ef4212f-c56f-508b-897c-741bceff55bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6836b996-4eee-5e2a-a99b-84973696e8e3","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5ccc9458-1b9d-5fa7-a565-2b00a539b9bd","slug":"assessment","fullItemName":"Assessment"},{"id":"729e434c-5849-59fb-b3ca-e7a86f26a8d6","slug":"investigations","fullItemName":"Investigations"},{"id":"0ce4b1b3-2e3a-5901-8e9c-981cea4198d7","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7a12e175-49ce-5c68-9c8f-756159646a3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"33ccae89-80e7-572a-b148-a81c781d0956","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"9b2fd470-be46-5a93-9f1a-502f0a8434dc","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ae3af6c6-eb78-5674-a94f-f5f087e5f812","slug":"pramipexole","fullItemName":"Pramipexole"},{"id":"1664194f-800a-54c6-bd79-106678653aaa","slug":"ropinirole","fullItemName":"Ropinirole"},{"id":"1a0b2fc3-18c3-51a9-968c-88bb51f2637f","slug":"rotigotine","fullItemName":"Rotigotine"},{"id":"87f55f71-dd3d-5e97-9c88-5fe3a78503db","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"a931371b-564c-5833-b5b4-d21ad3f1a361","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"6590cad9-132e-548c-b7ad-bf4375ef2caf","slug":"codeine","fullItemName":"Codeine"},{"id":"70676cc9-d1a4-5639-a227-62e452e13b2b","slug":"benzodiazepines-z-drugs","fullItemName":"Benzodiazepines and Z-drugs"},{"id":"fe9dc2de-9fbe-527f-b34b-446254f3d127","slug":"augmentation","fullItemName":"Augmentation"},{"id":"2203998a-e9f3-59c3-9132-50418bf47566","slug":"loss-of-efficacy","fullItemName":"Loss of efficacy"},{"id":"7d279d8d-8d6c-5c7d-8597-6ee343a7a574","slug":"impulse-control-disorders","fullItemName":"Impulse control disorders"}]},{"id":"0fadb6b8-91c2-57be-8c1d-2d3e31da6d60","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"afa91ee5-1f42-5cc6-b9ec-6ef16749457d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"baf472ab-f0f9-518a-8310-81583fd7d905","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9d31c719-7426-52cb-8343-b11a7bb8b5b3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a915b18c-93a0-5269-8ff1-021677ba9dd3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6e85726f-b5ea-5c2c-a886-f74ab46fbc6b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8ac2285b-b086-5b54-98d6-0ec8c43f05c2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8a058ec2-b2e0-5618-b51f-27102b964d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9b2fd470-be46-5a93-9f1a-502f0a8434dc","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"93f486f2-12d3-536c-8366-46f368a0a331","slug":"doses","fullItemName":"Doses","depth":3,"htmlHeader":"<!-- begin field 83df68bf-fd67-433a-87a9-ab3dcb422f28 --><h3>What doses of ropinirole are indicated for restless legs syndrome?</h3><!-- end field 83df68bf-fd67-433a-87a9-ab3dcb422f28 -->","summary":"","htmlStringContent":"<!-- begin item b2614213-033c-497a-8d37-0e920527c14f --><!-- begin field 7189c6f6-1610-4fed-aa53-a82e9b3a1c72 --><ul><li><strong>Initial dose:</strong> 250 micrograms 1–2 hours before bedtime (or anticipated onset of symptoms).</li><li><strong>Titration:</strong> if needed and tolerated, after 2 days increase to 500 micrograms for 5 days, then increase to 1 mg for 7 days, then increase weekly in steps of 500 micrograms.</li><li><strong>Maximum recommended dose:</strong> 4 mg daily.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>]</p><!-- end field 7189c6f6-1610-4fed-aa53-a82e9b3a1c72 --><!-- end item b2614213-033c-497a-8d37-0e920527c14f -->","subChapters":[]},{"id":"c49826c8-1c81-5019-a8c4-da75c5ef9056","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field b0f4acc1-ea30-401d-9f5b-cac23ea755e6 --><h3>What are the contraindications for ropinirole?</h3><!-- end field b0f4acc1-ea30-401d-9f5b-cac23ea755e6 -->","summary":"","htmlStringContent":"<!-- begin item 78660f78-6e9a-4c78-a01c-5bea69283632 --><!-- begin field 48566731-4fb7-4024-a53b-a9c8fb2c6968 --><ul><li><strong>Do not prescribe ropinirole for secondary restless legs syndrome,</strong> for example, caused by renal failure, iron deficiency anaemia, or pregnancy.</li><li><strong>Do not prescribe ropinirole for restless legs syndrome to:</strong><ul><li>Pregnant or breastfeeding women.</li><li>People with hypersensitivity to ropinirole or to any constituent in the tablet.</li><li>People with severe renal or hepatic impairment.</li><li>People with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>]</p><!-- end field 48566731-4fb7-4024-a53b-a9c8fb2c6968 --><!-- end item 78660f78-6e9a-4c78-a01c-5bea69283632 -->","subChapters":[]},{"id":"b8cb29fd-6885-591e-b3ab-0cdccbf36ac1","slug":"cautions","fullItemName":"Cautions","depth":3,"htmlHeader":"<!-- begin field 229a8c6e-bd84-438a-a2f5-4e62b4ddba32 --><h3>What are the cautions when using ropinirole?</h3><!-- end field 229a8c6e-bd84-438a-a2f5-4e62b4ddba32 -->","summary":"","htmlStringContent":"<!-- begin item 743c6179-b93f-41f1-83ef-19cf2641a3ae --><!-- begin field da123fd7-2b8c-4a37-8916-6128b4b94a9a --><ul><li><strong>Driving and using machinery</strong><ul><li>Ropinirole causes somnolence and episodes of sudden sleep onset in some people, and, uncommonly, without awareness or warning.</li><li>People should exercise caution while driving or operating machines, and must not drive or operate machinery if they experience episodes of sudden sleep onset.</li><li>The dose should be reduced or the drug stopped completely if sudden sleep onset occurs.</li><li>Also, exercise caution if taking other sedating drugs or alcohol in combination with ropinirole.</li></ul></li><li><strong>Psychotic disorders</strong><ul><li>Confusion, delirium, and hallucinations may occur in people treated with ropinirole.</li><li>People with psychotic disorders should only be treated with ropinirole if the potential benefits outweigh the risks.</li><li>Co-administration of antipsychotic drugs with ropinirole should be avoided.</li></ul></li><li><strong>People with severe cardiovascular disease</strong><ul><li>Blood pressure monitoring, especially at the beginning of treatment, is recommended owing to the risk of postural hypotension associated with dopaminergic therapy.</li></ul></li><li><strong>Renal impairment</strong><ul><li>The dose may need to be reduced in people with renal impairment. See the Summary of Product Characteristics for details.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>]</p><!-- end field da123fd7-2b8c-4a37-8916-6128b4b94a9a --><!-- end item 743c6179-b93f-41f1-83ef-19cf2641a3ae -->","subChapters":[]},{"id":"26fdf9cc-66f5-5055-b9d5-f776516e3e80","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 30e85c43-4e7c-4c43-bde7-c5e6181af1ba --><h3>What drug interactions are associated with ropirinole?</h3><!-- end field 30e85c43-4e7c-4c43-bde7-c5e6181af1ba -->","summary":"","htmlStringContent":"<!-- begin item 9dd46232-44d8-45de-9cc3-7c17959f09a7 --><!-- begin field 90e4ec69-6fd6-4d74-9915-5d51dfcd02ad --><ul><li><strong>The manufacturer of ropinirole advises to avoid concomitant use of antipsychotic drugs </strong>owing to an antagonism of effect.</li><li><strong>Ciprofloxacin has been demonstrated to inhibit the metabolism of ropinirole.</strong><ul><li>Theoretically, other drugs with similar mechanism of clearance may also affect ropinirole in a similar way such as enoxacin or fluvoxamine.</li><li>The clinical significance of these possible interactions are not clear but the manufacturer recommends a dose reduction of ropinirole if used concomitantly with these other drugs.</li></ul></li><li><strong>Smoking: </strong>also similarly affects the metabolism of ropinirole. Therefore if people stop or start smoking during treatment with ropinirole, dose adjustment maybe required.</li><li><strong>Metoclopramide:</strong> the manufacturer of ropinirole advises avoid concomitant use of metoclopramide owing to an antagonism of effect.</li><li><strong>Oestrogens:</strong> plasma concentration of ropinirole is increased by oestrogens. It may be necessary to adjust the ropinirole dose, in accordance with clinical response, if hormone replacement therapy or oestrogen-containing contraceptive pills are stopped or introduced during treatment with ropinirole.</li><li><strong>Warfarin:</strong> in people taking a vitamin K antagonist, such as warfarin and ropinirole, cases of unbalanced international normalized ratio (INR) have been reported. Increased clinical and biological surveillance (INR) is warranted.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Preston, 2020</a>]</p><!-- end field 90e4ec69-6fd6-4d74-9915-5d51dfcd02ad --><!-- end item 9dd46232-44d8-45de-9cc3-7c17959f09a7 -->","subChapters":[]},{"id":"3c1df354-0076-5bf1-a6be-c7bd5ff6b1fb","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ea42ed0b-3fd2-4445-9f53-051ace501ecc --><h3>What are the adverse effects of ropirinole?</h3><!-- end field ea42ed0b-3fd2-4445-9f53-051ace501ecc -->","summary":"","htmlStringContent":"<!-- begin item efb28eff-0d1e-4d16-a5d2-e33fe4425b15 --><!-- begin field cdee591e-7b8c-440a-b2bc-c09837a67756 --><ul><li><strong>The most commonly reported adverse drug reactions </strong>are nausea, headache, dizziness, and fatigue.  </li><li><strong>Less common but important adverse drug reactions </strong>include peripheral oedema, dopamine dysregulation syndrome (frequency unknown), hallucinations, confusion, delusions, sudden somnolence or drowsiness, <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/augmentation/\">augmentation</a>, and <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/impulse-control-disorders/\">impulse control disorders</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>]</p><!-- end field cdee591e-7b8c-440a-b2bc-c09837a67756 --><!-- end item efb28eff-0d1e-4d16-a5d2-e33fe4425b15 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}